SCHEMBL1345255

SCHEMBL1345255

NCCCc1c(C(=O)O)[nH]c2ccc(NC(=O)OCc3ccccc3)cc12

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 2/20 0.46
MGLL Q99685 1/20 0.46
TP53 P04637 2/20 0.44
MAPT P10636 2/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
ALDH1A1 P00352 1/20 0.44
TSHR P16473 1/20 0.44
ATM Q13315 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MCL1 Q07820 2/20 0.43
POLB P06746 1/20 0.42
ENPP2 Q13822 1/20 0.42
KDM1A O60341 1/20 0.42
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1345754 0.99 ROCK2 (0.45) ROCK2MGLLTP53MAPTNPC1
SCHEMBL1345722 0.84 MAPT (0.42) ROCK2MGLLTP53MAPTNPC1
SCHEMBL1345396 0.82 BRD4 (0.53) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL1346597 0.82 KDM4E (0.44) ALDH1A1TSHRMCL1POLB
Hydrochloric Acid SCHEMBL1347019 0.81 BRD4 (0.52) MAPTNPC1RAB9AALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL1343705 0.81 KDM4E (0.43) ALDH1A1TSHRMCL1POLB
SCHEMBL1343645 0.80 TRPM8 (0.64) MAPTALDH1A1SMN1; SMN2MCL1
Hydrochloric Acid SCHEMBL1345619 0.79 TRPM8 (0.62) MAPTALDH1A1SMN1; SMN2MCL1
SCHEMBL12131731 0.77 HTT (0.46) ALDH1A1SMN1; SMN2MCL1POLB
SCHEMBL14105899 0.76 MAPT (0.45) MAPTALDH1A1SMN1; SMN2MCL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063094-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-22 US disclosed
US-8063094-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-22 US disclosed
US-8063094-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-22 US disclosed
US-20110053955-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-03 US disclosed
US-20110053955-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-03 US disclosed
US-20110053955-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-03-03 US disclosed
WO-2008098096-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053955-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS MAPKAPK2, IL2, MAP3K2 ROCK2 348/4885MGLL 4664/4885TP53 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.